

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/602,024	06/24/2003	Bradley G. Thompson	16596-001001 7648	
26181	7590 06/13/2006		EXAMINER	
FISH & RICHARDSON P.C.			LI, BAO Q	
PO BOX 102	22 LIS, MN 55440-1022		ART UNIT	PAPER NUMBER
ministration of the real			1648	
			DATE MAILED: 06/13/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	1 4 10 10 10	T	
	Application No.	Applicant(s)	
	10/602,024	THOMPSON ET AL.	
Office Action Summary	Examiner	Art Unit	
	Bao Qun Li	1648	
The MAILING DATE of this communication appearing for Reply	opears on the cover sheet with the	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING [ - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO .136(a). In no event, however, may a reply be tild d will apply and will expire SIX (6) MONTHS from tte, cause the application to become ABANDONE	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on <u>28 (</u> 2a) This action is <b>FINAL</b> . 2b) 1 Th 3) Since this application is in condition for allows	is action is non-final.	osecution as to the merits is	
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.	
Disposition of Claims			
4)	awn from consideration.	•	
Application Papers			
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	ccepted or b) objected to by the e drawing(s) be held in abeyance. Se ction is required if the drawing(s) is ob	ee 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of:  1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicat ority documents have been receiv au (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s)  1) Notice of References Cited (PTO-892)	4)  Interview Summary Paper No(s)/Mail D		
<ol> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date</li> </ol>		Patent Application (PTO-152)	

Application/Control Number: 10/602,024 Page 2

Art Unit: 1648

### **DETAILED ACTION**

### **RCE**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 03/28/2006 has been entered. The RCE follows:

## Response to Amendment

This is a response to the amendment filed on 03/28/06. Claims 1-33 have been canceled. New claims 34-43 are added. Claims 34-43 are pending and considered by the examiner.

Please note any ground of rejection(s) that has not been repeated is removed. Text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

## Claim Rejections - 35 USC § 112

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

  The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 34-43 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
- 3. The test of an enablement or scope of enablement is whether one skilled in the art could make and use the claimed invention from the disclosure in the application coupled with information known in the art would render undue experimentation (See United States v. Theketronic Inc., 8USPQ2d 1217 (fed Cir. 1988). Whether undue experimentation is required is not based upon a single factor but rather a conclusion reached by weighting many factors. Theses factors were outlined in Ex parte Forman, 230 USPQ 546 (Bd. Pat. App. & Inter. 1986) and again in re Wands, 8USPQ2d 1400 (Fed. Cir. 1988), which are set forth bellow: 1). Nature of

Application/Control Number: 10/602,024

Art Unit: 1648

invention; 2). Scope of claims; 3). State of art; 4). Unpredictability; 5). Level of skill; 6). Number of working examples and 7). Amount of guidance presented in the specification.

- 4. The nature of invention is directed to an tumor phenotyping with certain oncolytic virus based on certain oncolytic virus can be preferentially proliferate well and kills certain oncogene mutated cancer cells.
- 5. The state of art teaches that certain oncolytic virus can be preferentially proliferate well and kills certain oncogene mutated cancer cells. For example, reovirus can proliferate well and kills ras oncogene mutated cancer cells, VSV is for INF resistant tumor; and Delta24 virus is specific for Rb mutant cancer cells. However, the scope of the claimed read on using mixture of such oncolytic virus for do the phenotype.
- 6. The specification only teaches an example of using reovirus for doing ras oncogene mutated cancer cells. However, the specification does not teach or give any guidance how to using mixture of oncolytic virus for doing the phenotyping.
- 7. It is unclear if the cancer cells are killed in the mixture of more than one oncolytic virus, how the phenotype can be determined because it is not able to determine which virus cause the cancer cells death.
- 8. The specification does not provide a sufficient evidence to support the broadly claimed scope of the invention.
- 9. Given the above analysis of the factors which the courts have determined are critical in asserting whether a claimed invention is enabled, it must be considered that the skilled artisan would have to conduct undue and excessive experimentation in order to practice the claimed invention.

## Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 571-272-0904. The examiner can normally be reached on 6:30 am to 3:30 pm.

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

BAOQUN LI, MD PATENT EXAMINER

Bao Qun Li Bao agant